Presse économique / Santé / Médical
SEATTLE -- (BUSINESS WIRE) -- June 6, 2005 -- Rosetta Biosoftware a lancé ce jour à l'occasion du Congrès annuel de la Société américaine de spectrométrie de masse (ASMS, American Society for Mass Spectrometry), qui s'est tenu à San Antonio (Texas), son système Rosetta Elucidator®. Rosetta Elucidator® est une plate-forme d'analyse des données sur l'expression des protéines qui possède des fonctionnalités permettant de faire progresser la recherche par la spectrométrie de masse d'un biomarqueur des protéines sans gel.
(BW)(WA-ROSETTA-BIOSOFTWARE)(MRK) Rosetta Biosoftware Introduces the Rosetta Elucidator Protein Expression Data Analysis System
Business Editors/Health/Medical Writers
SEATTLE--(BUSINESS WIRE)--June 6, 2005--Rosetta Biosoftware today introduced the Rosetta Elucidator(R) protein expression data analysis system with capabilities to support mass-spectrometry-based, gel-free protein biomarker discovery, at the annual meeting of the American Society for Mass Spectrometry (ASMS) in San Antonio, Texas. The system includes raw data management, LC/MS data processing for quantitative and differential analysis, protein identification and high level analysis at the peptide and protein level. "The growth of the proteomics field has resulted in rapid development and adoption of automated, high-throughput processing equipment. Modern mass spectrometers that are used for proteomics commonly generate gigabytes to terabytes of data per biological study," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware.
"An effective software solution must combine the capability to work with large and complex data sets with the flexibility to support customer-specific methodologies, as these have not been standardized in proteomics. To develop the Elucidator system, we leveraged our sdiv informatics platform to build a robust, flexible solution. The Elucidator system is empowered by an early access partnership with a major pharmaceutical company, and its pre-release version is being used to organize and analyze LC/MS data generated for a biomarker discovery program. Elucidator system features and capabilities are driven by customer needs, and we are excited to bring this new system to the market." The Elucidator system's advanced data management capabilities allow users to effectively organize, search for and retrieve raw and processed protein expression data.
The application serves as a core integrator for proteomics research by working directly with select instrument APIs, sample annotation systems, and common protein ID search engines. In addition, it provides a suite of advanced statistical analysis and visualization tools for data mining and discovery of potential protein biomarkers and proteins that are differentially expressed among different phenotypes or drug treatments.
The Elucidator system combines these data management and analysis capabilities with the flexibility of a highly customizable environment: users can incorporate organization-specific workflows into customized visual scripts that leverage Elucidator system statistical tools and customer-proprietary algorithms, as well as those available in the public domain. The Rosetta Elucidator product line will be available in flexible configurations, designed to meet the needs of both large and small organizations.
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its enterprise software solutions, including the Rosetta Resolver and Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research.
Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co
., Inc. (NYSE:MRK).
More information about Rosetta Biosoftware is available at www.rosettabio.com.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.
No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference. Rosetta Resolver and Rosetta Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.
CONTACT: Rosetta Biosoftware Kenna Mawk, 206-992-5359
KEYWORD: WASHINGTON Biomedical
INDUSTRY KEYWORD: MEDICAL DEVICES BIOTECHNOLOGY SOFTWARE PRODUCT
SOURCE: Rosetta Biosoftware